Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +1.23% | -16.24% | +7.84% |
Financials (USD)
Sales 2024 * | 25.81M | Sales 2025 * | 77.52M | Capitalization | 406M |
---|---|---|---|---|---|
Net income 2024 * | -186M | Net income 2025 * | -163M | EV / Sales 2024 * | 15.7 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.24 x |
P/E ratio 2024 * |
-2.32
x | P/E ratio 2025 * |
-2.6
x | Employees | 285 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.99% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
1 day | +1.23% | ||
1 week | -16.24% | ||
Current month | -31.25% | ||
1 month | -32.38% | ||
3 months | +26.92% | ||
6 months | +42.86% | ||
Current year | +7.84% |
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +4.23% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.65 | +1.23% | 2,987,234 |
24-04-18 | 1.63 | +0.62% | 3,715,007 |
24-04-17 | 1.62 | -4.42% | 5,561,536 |
24-04-16 | 1.695 | -9.36% | 4,591,788 |
24-04-15 | 1.87 | -5.08% | 3,492,458 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.84% | 401M | |
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |
- Stock Market
- Equities
- LXRX Stock